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sample collection dates back to 2003. This suggests that 
candidatus B mayonii is a newly-emerged genospecies.  
The discovery of a novel tick-borne pathogen poses 
new challenges to diagnostics, therapy, and public 
health surveillance. As our environment and settlement 
patterns continue to change and the global human 
population continues to grow, we need eﬀ ective 
surveillance and intervention strategies to control tick-
borne diseases.
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Early HIV treatment to forestall drug resistance
In this issue, Ravindra Gupta and colleagues1 present 
compelling ﬁ ndings of the epidemiology of HIV drug 
resistance. Based on the results of a collaborative study 
termed TenoRes, the researchers clearly document 
that the prevalence of HIV drug resistance against the 
commonly used antiretroviral drug tenofovir is far higher 
than expected, especially in sub-Saharan Africa. This result 
is disconcerting because it had previously been thought 
that tenofovir might be less prone to development of 
drug resistance than other compounds. The investigators 
went on to show that a strong predictor of tenofovir 
resistance was a CD4 cell count of less than 100 cells per 
μL, suggesting an HIV-damaged immune system. The 
use of lamivudine compared with emtricitabine was also 
associated with an increased risk of tenofovir resistance, a 
ﬁ nding that might reﬂ ect the longer intracellular half-life 
that is associated with the active form of emtricitabine 
compared with lamivudine.2 The ﬁ nding that HIV drug 
resistance has occurred at higher than expected levels 
indicates a need to develop treatment regimens that 
will be less prone to this problem, which is one that 
should probably have been anticipated as an unavoidable 
outcome of the successful HIV drug rollout programmes 
that have helped to save millions of lives around the 
world in the past several decades. 
Among other considerations, a new pro-drug of 
tenofovir termed tenefovir alafenamide fumarate might 
be less prone to development of drug resistance because of 
lower toxic eﬀ ects than tenofovir itself, which is associated 
with loss of bone mineral density and raised creatinine 
concentrations.3 However, this might not necessarily 
translate into lower levels of drug resistance because the 
same mutation at position K65R in reverse transcriptase 
causes resistance to both drugs and might be more prone 
to develop in subtype C viruses that were assessed in this 
and other studies.4–8 Unfortunately, subtype C viruses are 
predominant in many low-income and middle-income 
countries8 and limited availability of integrase inhibitors 
in such settings for use in ﬁ rst-line therapy despite the fact 
that their use is now recommended by almost all treatment 
guidelines, will potentially exacerbate this problem.
Another important ﬁ nding of this study is that drug 
resistance was more likely to develop in individuals who 
have low CD4 cell counts due to HIV disease progression. 
Aside from focusing attention on the important role 
that a functional immune system can play in mitigating 
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disease progression and development of drug resistance, 
we also know that an individual has the best chance 
of attaining long-term treatment success by starting 
treatment as soon as possible after diagnosis when CD4 
concentrations are high.9 Therefore, the identiﬁ cation 
of individuals as HIV positive as eﬃ  ciently and as soon 
as possible is important; WHO has recently introduced 
a strategy termed 90-90-90 that seeks to identify 90% 
of people in the world who are HIV positive, to treat 
90% of such people, and to attain a non-detectable viral 
load in 90% of such cases after treatment initiation. The 
hope is that this will also serve to prevent onward HIV 
transmission because individuals who have undetectable 
viraemia are unlikely to be infectious for their partners.10–12
Of course, the success of the WHO 90-90-90 guide-
lines depends on convincing a very high proportion of 
high-risk individuals who are unaware of their HIV status 
to agree to be tested. In this context, a sound argument 
can be made that more eﬀ ective incentivisation is 
urgently needed and perhaps a ﬁ nancial oﬀ ering 
could make a diﬀ erence. Although the costs of such 
a programme could be high, these would almost 
certainly be dwarfed by the costs involved in providing 
antiretroviral treatment to people who might become 
infected by those who have not yet undergone therapy 
because their HIV status is unknown.
Altogether, the results of this study are a reminder that 
the problems of HIV drug resistance and transmitted 
drug resistance are very real, especially in developing 
country settings, and that there is a need for enhanced, 
cost-eﬀ ective tests that can screen for drug resistance 
in parts of the world in which such tests are often not 
aﬀ ordable as well as for more eﬀ ective screening for HIV 
infection in the ﬁ rst place.
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Mounting evidence for use of artemisinin derivatives for 
malaria in early pregnancy
Malaria in pregnancy can be a clinically devastating con-
dition, and exacts substantial morbidity and mortality 
in vulnerable populations particularly in the developing 
world.1 Its complications are conspicuous in pregnant 
women who are prone to severe anaemia, and their 
oﬀ spring face possibilities of still births, miscarriages, or 
low birthweight.2 
To prevent malaria in pregnancy and its 
complications, various measures to reduce human–
malaria vector contact such as the use of insecticide-
treated nets and insecticide residual spraying 
are applied extensively. Chemoprevention with 
sulfadoxine–pyrimethamine is used to mitigate 
adverse pregnancy outcomes, but is also largely 
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